News | May 16, 2025
Sanofi India posts 27% growth in operating profits in Q1 2025
Standalone profit from operations for the quarter were Rs. 162 crores
Standalone profit from operations for the quarter were Rs. 162 crores
EBITDA before special items decreases to €4.08 billion (7.4%)
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
Delivers robust earnings performance, successfully navigating a dynamic environment
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Rising demands and advancements in eye care drive growth
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Awards highlight Avantor's commitment to the Biopharma industry
FlexiTubes will showcase range of eco-friendly and innovative tube options
Subscribe To Our Newsletter & Stay Updated
